Market Research Logo

Endometriosis - Pipeline Review, H2 2015

Endometriosis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Endometriosis - Pipeline Review, H2 2015’, provides an overview of the Endometriosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Endometriosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Endometriosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Endometriosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Endometriosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Endometriosis Overview
Therapeutics Development
Pipeline Products for Endometriosis - Overview
Pipeline Products for Endometriosis - Comparative Analysis
Endometriosis - Therapeutics under Development by Companies
Endometriosis - Therapeutics under Investigation by Universities/Institutes
Endometriosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Endometriosis - Products under Development by Companies
Endometriosis - Products under Investigation by Universities/Institutes
Endometriosis - Companies Involved in Therapeutics Development
AbbVie Inc.
Addex Therapeutics Ltd
APAvadis Biotechnologies Srl
Astellas Pharma Inc.
Bayer AG
Dongkook Pharmaceutical Co., Ltd.
ElexoPharm GmbH
EndoCeutics, Inc.
Enteris BioPharma, Inc.
Euroscreen S.A.
Evotec AG
Forendo Pharma Oy
GlaxoSmithKline Plc
Kissei Pharmaceutical Co., Ltd.
Lipicard Technologies Limited
Nippon Shinyaku Co., Ltd.
Orphagen Pharmaceuticals, Inc.
Philogen S.p.A.
Repros Therapeutics Inc.
SK Chemicals Co., Ltd.
Takeda Pharmaceutical Company Limited
ValiRx Plc
Endometriosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(anastrozole + levonorgestrel) - Drug Profile
acolbifene hydrochloride + prasterone + GnRH agonist - Drug Profile
ADX-68692 - Drug Profile
ASP-1707 - Drug Profile
BAY-1128688 - Drug Profile
bentamapimod - Drug Profile
Drug to Inhibit C-Jun for Endometriosis - Drug Profile
Drugs for Endometriosis - Drug Profile
Drugs for Endometriosis and Uterine Fibroids - Drug Profile
elagolix sodium - Drug Profile
epelsiban besylate - Drug Profile
ESN-364 - Drug Profile
EVE-104 - Drug Profile
FP-5677 - Drug Profile
goserelin - Drug Profile
KLH-2109 - Drug Profile
leuprolide acetate - Drug Profile
LT-6121 - Drug Profile
Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile
NCE-403 - Drug Profile
NS-580 - Drug Profile
Peptides for Cancer and Endometriosis - Drug Profile
Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis - Drug Profile
PGL-2001 - Drug Profile
Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile
relugolix - Drug Profile
Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile
Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile
SR-16234 - Drug Profile
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
telapristone acetate - Drug Profile
Tetravil - Drug Profile
triptorelin pamoate - Drug Profile
VAL-201 - Drug Profile
vilaprisan - Drug Profile
VPE-001 - Drug Profile
VPEA-004 - Drug Profile
Endometriosis - Recent Pipeline Updates
Endometriosis - Dormant Projects
Endometriosis - Discontinued Products
Endometriosis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Endometriosis, H2 2015
Number of Products under Development for Endometriosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Endometriosis - Pipeline by AbbVie Inc., H2 2015
Endometriosis - Pipeline by Addex Therapeutics Ltd, H2 2015
Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H2 2015
Endometriosis - Pipeline by Astellas Pharma Inc., H2 2015
Endometriosis - Pipeline by Bayer AG, H2 2015
Endometriosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2015
Endometriosis - Pipeline by ElexoPharm GmbH, H2 2015
Endometriosis - Pipeline by EndoCeutics, Inc., H2 2015
Endometriosis - Pipeline by Enteris BioPharma, Inc., H2 2015
Endometriosis - Pipeline by Euroscreen S.A., H2 2015
Endometriosis - Pipeline by Evotec AG, H2 2015
Endometriosis - Pipeline by Forendo Pharma Oy, H2 2015
Endometriosis - Pipeline by GlaxoSmithKline Plc, H2 2015
Endometriosis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015
Endometriosis - Pipeline by Lipicard Technologies Limited, H2 2015
Endometriosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015
Endometriosis - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2015
Endometriosis - Pipeline by Philogen S.p.A., H2 2015
Endometriosis - Pipeline by Repros Therapeutics Inc., H2 2015
Endometriosis - Pipeline by SK Chemicals Co., Ltd., H2 2015
Endometriosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Endometriosis - Pipeline by ValiRx Plc, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Endometriosis Therapeutics - Recent Pipeline Updates, H2 2015
Endometriosis - Dormant Projects, H2 2015
Endometriosis - Dormant Projects (Contd..1), H2 2015
Endometriosis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Endometriosis, H2 2015
Number of Products under Development for Endometriosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report